Iga Swiatek has accepted a one-month suspension from the International Tennis Integrity Agency (ITIA) after testing positive for a banned substance.

The 23-year-old, the current world No. 2, failed a doping test for the prohibited substance trimetazidine (TMZ) in an out-of-competition sample in August 2024.

The ITIA confirmed that an investigation determined the source was a contaminated regulated medication, concluding that Swiatek bore no significant fault or negligence.

The five-time Grand Slam champion will be able to return in time for the Australian Open, which begins on January 12, having already served 22 days of her suspension with the process ongoing.

Swiatek was informed of her positive test in September and given a provisional suspension, which she successfully appealed. As such, the positive test could not be revealed publicly due to the Tennis Anti-Doping Programme Rules.

During her provisional suspension, Swiatek was absent from the Asian hard-court swing – the Korea Open, China Open and Wuhan Open – citing “personal reasons”. She was able to compete in the season-ending WTA Finals in Riyadh and the Billie Jean King Cup finals.

“The International Tennis Integrity Agency (ITIA) today confirms that Iga Swiatek, a 23-year-old tennis player from Poland, has accepted a one-month suspension under the Tennis Anti-Doping Programme, after testing positive for the prohibited substance trimetazidine (TMZ) in an out-of-competition sample in August 2024. 

“The ITIA accepted that the positive test was caused by the contamination of a regulated non-prescription medication (melatonin), manufactured and sold in Poland that the player had been taking for jet lag and sleep issues, and that the violation was therefore not intentional. This followed interviews with the player and their entourage, investigations, and analysis from two WADA-accredited laboratories. 

“In relation to the player’s level of fault, as the contaminated product was a regulated non-prescription medication in the player’s country of origin and purchase and considering all the circumstances of its use (and other contaminated product cases under the World Anti-Doping Code), the player’s level of fault was considered to be at the lowest end of the range for ‘No Significant Fault or Negligence’.

“The ITIA therefore offered a one-month suspension to Swiatek and on November 27, 2024, the player, currently ranked number two in women’s singles, formally admitted the ADRV and accepted the sanction.

“The player was provisionally suspended from September 22 until October 4, missing three tournaments, which counts towards the sanction, leaving eight days remaining. In addition, the player also forfeits prize money from the Cincinnati Open, the tournament directly following the test.”

“The WTA acknowledges the decision by the International Tennis Integrity Association (ITIA) – which administers the Tennis Anti-Doping Program (TADP) – in issuing a one-month suspension to Iga Swiatek, following the identification of a contaminated regulated medication (melatonin) as the source for her positive test for the prohibited substance Trimetazidine.

“The WTA fully supports Iga during this difficult time. Iga has consistently demonstrated a strong commitment to fair play and upholding the principles of clean sport, and this unfortunate incident highlights the challenges athletes face in navigating the use of medications and supplements.

“The WTA remains steadfast in our support for a clean sport and the rigorous processes that protect the integrity of competition. We also emphasise that athletes must take every precaution to verify the safety and compliance of all products they use, as even unintentional exposure to prohibited substances can have significant consequences.

“We will continue to work closely with our athletes to provide education and resources that empower athletes to make informed decisions and maintain the highest standards of integrity in our sport.”